Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Non Operating Income (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Non Operating Income for 6 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 122.27% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.3 million, a 201.95% increase, with the full-year FY2025 number at $26.3 million, up 187464.29% from a year prior.
  • Non Operating Income was $5.7 million for Q4 2025 at Relay Therapeutics, down from $6.2 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $31.0 million in Q4 2023 to a low of -$25.8 million in Q4 2024.
  • A 5-year average of $2.0 million and a median of $16000.0 in 2022 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: plummeted 108114.29% in 2023, then skyrocketed 714400.0% in 2025.
  • Relay Therapeutics' Non Operating Income stood at -$563000.0 in 2021, then soared by 1354.17% to $7.1 million in 2022, then soared by 339.68% to $31.0 million in 2023, then tumbled by 183.01% to -$25.8 million in 2024, then soared by 122.27% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Non Operating Income are $5.7 million (Q4 2025), $6.2 million (Q3 2025), and $14.3 million (Q2 2025).